BUN-to-ALB ratio as an effective predictor of 30 day mortality in ADHF patients in eastern China

Xin Huang1,2,3,4, Chao Wang1,2,3,4, Shiming He1,2,3,4

  • 1Jiangxi Medical College, Nanchang University, Nanchang, China.

ESC Heart Failure
|April 2, 2025
PubMed

Insights

The blood urea nitrogen-to-albumin ratio (BAR) effectively predicts short-term mortality in acute decompensated heart failure (ADHF) patients. A BAR threshold of 0.33 indicates a significantly higher risk of 30-day mortality.

Area of Science:

  • Cardiology
  • Biomarkers
  • Prognostic Indicators

Background:

  • Heart failure (HF) prognosis assessment is crucial.
  • The blood urea nitrogen-to-albumin ratio (BAR) is a potential prognostic indicator for HF.
  • The prognostic value of BAR in Chinese patients with acute decompensated HF (ADHF) requires further investigation.

Purpose of the Study:

  • To evaluate the prognostic value of BAR for short-term mortality in ADHF patients.
  • To determine the optimal BAR threshold for predicting 30-day mortality in ADHF.
  • To explore the relationship between BAR and prognosis in a Chinese population.

Main Methods:

  • Analysis of 1421 ADHF patients admitted between 2019-2022.
  • Utilized Cox regression models to assess BAR's role in short-term prognosis.
  • Employed restricted cubic spline and ROC curve analyses to determine nonlinear relationships, thresholds, and predictive accuracy for 30-day mortality.

Main Results:

  • A high BAR (≥0.33) was significantly associated with increased 30-day mortality risk (HR: 3.25).
  • The mortality rate was substantially higher in the high-BAR group (12.46%) compared to the low-BAR group (1.26%).
  • Restricted cubic spline analysis revealed a nonlinear association (P<0.001) with a threshold between 0.3-0.5. ROC analysis yielded an AUC of 0.84 for predicting 30-day mortality.

Conclusions:

  • BAR is an effective predictor of short-term prognosis in ADHF patients.
  • An optimal BAR threshold of 0.33 was identified for predicting 30-day mortality.
  • Findings are based on clinical data from the Jiangxi population, highlighting BAR's utility in this demographic.
Abstract